ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE
A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 555 participants.
Also called NCT05746559
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 555 participants
- Registry
-
NCT05746559 -
2022-501802-36
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Australia, Brazil, Canada, China, France, Germany, Hong Kong SAR China, India, Israel, Italy, Japan, Netherlands, Poland, South Korea, Spain, Taiwan, Türkiye, United Kingdom
- Registry status
- Terminated
Technical summary
Registry record NCT05746559. Randomized; quadruple masking; primary purpose treatment. Start 2023-04-06 (actual); primary completion 2025-10-07 (actual). Results posted on 2026-10-29.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE
- Acronym
- ARTEMIS
- Condition
- Chronic Kidney Disease
- Condition
- CKD (chronic kidney disease)
- Condition
- Cardiac Disease
- Condition
- Cardiopulmonary Bypass
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Ravulizumab
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
Record details
- Record id
cardio:ct-nct05746559- Content hash
12ab31c4c470df5795d53147567190cbd8fb9c248e6cf442f2710a2579c5a715